FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
Pharmacodynamic data show comprehensive target engagement after treatment with CPI-0209 monotherapyOral...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
CONSTELLATION PHARMACEUTICALS INC false 0001434418 0001434418 2021-06-02 2021-06-02 UNITED...
Royalty Pharma to provide tailored funding solution to enable MorphoSys’ acquisition of Constellation PharmaceuticalsInvestment is anchored by...
Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in...
CAMBRIDGE, Mass., May 31, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a...
Dosing underway in the Phase 3 MANIFEST-2 clinical trialRecommended Phase 2 dose determined for CPI-0209 and...
false Q1 CONSTELLATION PHARMACEUTICALS INC 0001434418 --12-31 true true 0 0 P10Y P10Y P10Y P8Y21D P8Y3M25D P8Y3M25D P7Y2M15D P6...
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.